Overview
New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs
Symposium Highlights!
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis.
Join an expert faculty panel as they discuss the role of new and emerging anti-CGRP mAbs in migraine treatment, and implications for patients. The 60-minute video-based highlights activity will integrate didactic presentation with polling questions, as experts review clinical evidence, guideline recommendations, and shared decision-making strategies.
This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.
Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are an emerging preventative migraine therapy class that offers benefits over traditional systemic prophylaxis. This activity will review the emerging role of anti-CGRP mAbs and provide clinicians with strategies to improve patient adherence.
Upon completion of this activity, participants will be able to:
- Evaluate and discuss the efficacy, safety, and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
- Develop effective strategies for improving patient adherence to therapies
- Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management
- Evaluate and discuss the efficacy, safety, and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
- Develop effective strategies for improving patient adherence to therapies
- Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management
Sponsored by the Academy for Continued Healthcare Learning (ACHL)
Supported by an educational grant from Lundbeck.
The Role of CGRPs in Evidence-Based Migraine Treatment
I. Unmet medical needs for migraine prevention
II. The promise of anti-CGRP mAbs in migraine prevention
Moving Toward Precision Medicine for Migraine in the CGRP Era
I. Expert recommendations on use of anti-CGRP mAbs in practice
II. Personalizing treatment decisions
III. Shared decision-making strategies
Lawrence C. Newman, MD, FAHS, FAAN (Chair)
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
Jessica Ailani, MD, FAHS, FAAN
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
Richard B. Lipton, MD, FAHS, FAAN
Professor and Vice Chair, Neurology
Albert Einstein College of Medicine
Director, Montefiore Headache Center
Bronx, NY
The following financial relationships have been provided:
Lawrence C. Newman, MD, FAHS, FAAN (Chair)
Advisory Board: Allergan, Amgen, Eli Lilly and Company, Supernus, Theranica
Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and Company, Impel, Neurodiem,
Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company, Teva
Richard B. Lipton, MD, FAHS, FAAN
Advisory Board, Consulting Agreements, or Honorarium Recipient: Allergan, Amgen, Avanir, Biohaven,
Biovision, Boston Scientific, Dr Reddy’s (Promius), Electrocore, Eli Lilly and Company, eNeura
Therapeutics, Equinox, GlaxoSmithKline, Lundbeck (Alder), Merck, Pernix, Pfizer, Supernus, Teva,
Trigemina, Vector, Vedanta
Stockholder: Biohaven Holdings, eNeura Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity nor for the generation of the certificate.
For questions, contact Charles Peterson at cpeterson@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
